Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

TPR   neutral

Noted as a new partner in UK and Europe without specific performance context

---

LXEO   positive

The company announced positive interim clinical trial data showing good safety profile, robust transduction, meaningful increases in PKP2 protein expression (93-162%), and clinically meaningful improvement or stabilization in arrhythmia burden across the majority of participants. No serious safety concerns were reported, and the therapy addresses an unmet medical need in a rare disease affecting approximately 60,000 people in the US.

---

#gene therapy #AAV #arrhythmogenic cardiomyopathy #PKP2 #Phase I/II trial #cardiac disease #protein expression #clinical trial data

LXEO